A study on giving amino acids to patients to reduce kidney injury after liver transplant

The efficacy of Intravenous amino acids in reducing the occurrence of AKI after Live Donor Liver Transplant: An Open Label Randomized Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101335

Enrollment

100

Registered

2026-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver Health Condition 2: K703- Alcoholic cirrhosis of liver Health Condition 3: K743- Primary biliary cirrhosis Health Condition 4: K717- Toxic liver disease with fibrosisand cirrhosis of liver Health Condition 5: C220- Liver cell carcinoma Health Condition 6: C221- Intrahepatic bile duct carcinoma

Interventions

Intervention1: Intravenous Amino Acid with standard of Care: Continuous infusion of L-amino acids mixture in a dose of 2 g per kg dry body weight per day (to a maximum 100 g per day) after induction

Eligibility

Inclusion criteria

Inclusion criteria: All Living donor liver transplant recipient (LDLT) Recipient Signed informed consent

Exclusion criteria

Exclusion criteria: 1. Negative consent. 2. Pediatric LDLT. 3. ALF patient undergoing LDLT. 4. Patients on intermittent or continuous renal replacement therapy. 5. Patients with eGFR less then 40 ml per min per 1.73 m2. 6. SLKT and prior Kidney transplant. 7. Patient has a hypersensitivity (known allergy) to one or more of the included amino acids. 8. Patient has a known congenital alteration of amino acid metabolism.

Design outcomes

Primary

Measure	Time frame
To compare the incidence of early post transplant AKI (within 1st week) in patients undergoing LDLT between L-amino acids infusion and standard treatment groups.Timepoint: within 1st week	—

Secondary

Measure	Time frame
To Determine the severity of early post Liver transplant AKITimepoint: within 1st week;To determine eGFR at Day 30 and 90 post transplant.Timepoint: Day 90;The use and duration of kidney-replacement therapy during the hospital stay Timepoint: 1 month;To determine the factors responsible for occurrence of early post-transplant AKITimepoint: within 1st week;In Hospital MortalityTimepoint: 1 month;The duration of mechanical ventilation, ICU stay and in hospital stay.Timepoint: 1 month;Major Morbidity (Clavien-Dindo more than equal to 3) and Early Graft DysfunctionTimepoint: 1 month	—

Measure

Time frame

To Determine the severity of early post Liver transplant AKITimepoint: within 1st week;To determine eGFR at Day 30 and 90 post transplant.Timepoint: Day 90;The use and duration of kidney-replacement therapy during the hospital stay Timepoint: 1 month;To determine the factors responsible for occurrence of early post-transplant AKITimepoint: within 1st week;In Hospital MortalityTimepoint: 1 month;The duration of mechanical ventilation, ICU stay and in hospital stay.Timepoint: 1 month;Major Morbidity (Clavien-Dindo more than equal to 3) and Early Graft DysfunctionTimepoint: 1 month

—

Countries

India

Contacts

Public ContactDr Nilesh S Patil

ILBS

dr.nils.p@gmail.com9911594576

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026